4D Molecular inks collaboration deal on machine learning technology

• 4D Molecular Therapeutics (NASDAQ:FDMT) announces a new collaboration with investigators at the University of California, Berkeley focused on expanding the vector invention power of 4DMT’s Therapeutic Vector Evolution platform.
• The collaboration intends to apply machine learning technology to the AAV vector capsid datasets generated from 4DMT’s platform.
• The application of machine learning to 4DMT’s Therapeutic Vector Evolution and its datasets represents an opportunity to leverage an enabling technology to invent new vectors for use in targeted gene therapy products, the company said.